戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 se-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation.
2 velopment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
3 rapy to treat malignancies in the context of allogeneic hematopoietic stem cell transplantation.
4 , which include medical therapy, surgery, or allogeneic hematopoietic stem cell transplantation.
5 potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation.
6 ading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation.
7 nd were greater than 1 year from the time of allogeneic hematopoietic stem cell transplantation.
8 nic graft-versus-host disease (GVHD) follows allogeneic hematopoietic stem cell transplantation.
9 cute myelogenous leukemia and was undergoing allogeneic hematopoietic stem cell transplantation.
10 nd immune recovery, and one had a subsequent allogeneic hematopoietic stem cell transplantation.
11 han those in molecular remission, even after allogeneic hematopoietic stem cell transplantation.
12 t's response to therapy, and improvements in allogeneic hematopoietic stem cell transplantation.
13 se with limited myeloid reconstitution after allogeneic hematopoietic stem cell transplantation.
14 atients who survived more than 2 years after allogeneic hematopoietic stem cell transplantation.
15 ell repertoire, which would be of benefit in allogeneic hematopoietic stem cell transplantation.
16 used increasingly as an immunosuppressant in allogeneic hematopoietic stem cell transplantation.
17 associated with adverse clinical outcomes in allogeneic hematopoietic stem cell transplantation.
18 bloodstream infection in patients undergoing allogeneic hematopoietic stem cell transplantation.
19 s are the main goals of T-cell therapy after allogeneic hematopoietic stem cell transplantation.
20 mbotic microangiopathy that occurs following allogeneic hematopoietic stem cell transplantation.
21  a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation.
22 ents with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation.
23 host responses that influence the outcome of allogeneic hematopoietic stem cell transplantation.
24 n is a rare but fatal complication following allogeneic hematopoietic stem cell transplantation.
25  is presently no curative therapy other than allogeneic hematopoietic stem cell transplantation.
26 crimal gland graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
27 r cell leukemia is a rare complication after allogeneic hematopoietic stem cell transplantation.
28 ere examined in a mouse model of MHC-matched allogeneic hematopoietic stem cell transplantation.
29 able advances have been made in the field of allogeneic hematopoietic stem cell transplantation.
30 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.
31 s syndrome is a frequent condition following allogeneic hematopoietic stem cell transplantation.
32 n animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.
33                    Only 7 patients underwent allogeneic hematopoietic stem cell transplantation.
34 with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.
35 t disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation.
36 y regulated post-transplantation immunity in allogeneic hematopoietic stem-cell transplantation.
37 sociated with survival after unrelated-donor allogeneic hematopoietic stem-cell transplantation.
38 rs for male recipients worsen the outcome of allogeneic hematopoietic stem-cell transplantation.
39 -versus-host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation.
40 utations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.
41 onse to DBY in a recipient of sex mismatched allogeneic hematopoietic stem-cell transplantation.
42 e CD19 specific, for adoptive transfer after allogeneic hematopoietic stem-cell transplantation.
43 ents with multiple myeloma who relapse after allogeneic hematopoietic stem-cell transplantation.
44  function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation.
45 dition, the affected infant was treated with allogeneic hematopoietic stem-cell transplantation.
46 ading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation.
47                               The success of allogeneic hematopoietic stem cell transplantation, a ke
48 osphorylase replacement has been achieved by allogeneic hematopoietic stem cell transplantation, a pr
49 ate of a subgroup of 9 patients who received allogeneic hematopoietic stem cell transplantation after
50  phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSC
51 auses significant morbidity and mortality in allogeneic hematopoietic stem cell transplantation (aHSC
52  244 samples from 26 pediatric recipients of allogeneic hematopoietic stem cell transplantation (AHSC
53 mune responses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSC
54                             More than 25,000 allogeneic hematopoietic stem cell transplantations (all
55 e of adult intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo
56                                              Allogeneic hematopoietic stem cell transplantation (allo
57                                     Although allogeneic hematopoietic stem cell transplantation (allo
58 NX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo
59                                           In allogeneic hematopoietic stem cell transplantation (allo
60 rsus-host disease (GVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation (allo
61                          Patients undergoing allogeneic hematopoietic stem cell transplantation (allo
62 butes to the risk of severe infections after allogeneic hematopoietic stem cell transplantation (allo
63    The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (allo
64 donor vs host MHC on their development after allogeneic hematopoietic stem cell transplantation (allo
65 e is known of HEV infection in recipients of allogeneic hematopoietic stem cell transplantation (allo
66 llowing reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo
67 (GVHD) is still a leading complication after allogeneic hematopoietic stem cell transplantation (allo
68 ngiogenesis has not been investigated during allogeneic hematopoietic stem cell transplantation (allo
69 regs in healthy donors and in patients after allogeneic hematopoietic stem cell transplantation (allo
70 D) donor lymphocyte infusion (DLI) after TCD allogeneic hematopoietic stem cell transplantation (allo
71                                              Allogeneic hematopoietic stem cell transplantation (allo
72 ricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo
73 ded for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (allo
74                                           In allogeneic hematopoietic stem cell transplantation (allo
75                        The clinical value of allogeneic hematopoietic stem cell transplantation (allo
76 gainst certain malignancies in recipients of allogeneic hematopoietic stem cell transplantation (allo
77 elapse-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo
78 OF REVIEW: Despite the curative potential of allogeneic hematopoietic stem cell transplantation (allo
79              Delays in immune recovery after allogeneic hematopoietic stem cell transplantation (allo
80     Bacteremia is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo
81                         The clinical goal of allogeneic hematopoietic stem cell transplantation (allo
82  is a frequent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo
83 s.-host disease (cGVHD) is a complication of allogeneic hematopoietic stem cell transplantation (allo
84       Whether CD20 influences outcomes after allogeneic hematopoietic stem cell transplantation (allo
85   Donor T cells contribute to the success of allogeneic hematopoietic stem cell transplantation (allo
86 myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo
87 herapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo
88                                  However, in allogeneic hematopoietic stem cell transplantation (allo
89             Prospective data on the value of allogeneic hematopoietic stem cell transplantation (allo
90                                              Allogeneic hematopoietic stem cell transplantation (allo
91                      Much of the efficacy of allogeneic hematopoietic stem cell transplantation (allo
92  on alloreactive T cells in recipients of an allogeneic hematopoietic stem cell transplantation (allo
93  immunity, have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo
94                                              Allogeneic hematopoietic stem cell transplantation (allo
95 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo
96 ental graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo
97 ed by monocytes, it has been speculated that allogeneic hematopoietic stem cell transplantation (allo
98 y graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo
99                                    Reporting allogeneic hematopoietic stem cell transplantation (allo
100 elphia (Ph) chromosome to chemotherapy or to allogeneic hematopoietic stem-cell transplantation (allo
101                         The effectiveness of allogeneic hematopoietic stem-cell transplantation (allo
102 kemia (GVL) because patients relapsing after allogeneic hematopoietic stem-cell transplantation (allo
103 s (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo
104 lignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (allo
105 .4 days (interquartile range, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 1
106  developed in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 5
107 sease (cGVHD) is a notorious complication of allogeneic hematopoietic stem cell transplantation and c
108 report that tumor-directed vaccination after allogeneic hematopoietic stem cell transplantation and d
109  promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and i
110 th advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and m
111 e first lymphoid population recovering after allogeneic hematopoietic stem cell transplantation and p
112 mmunodeficiency (SCID) can be cured by using allogeneic hematopoietic stem cell transplantation, and
113  (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and
114 infection risk, (2) improving the outcome of allogeneic hematopoietic stem cell transplantation, and
115  disease (aGVHD) is the main complication of allogeneic hematopoietic stem cell transplantation, and
116 nce the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but h
117 t disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation but t
118                                              Allogeneic hematopoietic stem-cell transplantation can c
119                                              Allogeneic hematopoietic stem cell transplantation combi
120    Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation conti
121  the fecal microbiota of patients undergoing allogeneic hematopoietic stem cell transplantation demon
122 rvival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do no
123 linical experience with adoptive transfer of allogeneic hematopoietic stem cell transplantation donor
124 D14(+)CD16(+) monocytes can be isolated from allogeneic hematopoietic stem cell transplantation donor
125 -) and CD14(+)CD16(+) monocytes from healthy allogeneic hematopoietic stem cell transplantation donor
126 e on their nationwide retrospective study of allogeneic hematopoietic stem cell transplantation for a
127 s (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for m
128 t molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for M
129 ent with acute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from
130 ioimmunotherapy, therapeutic vaccination and allogeneic hematopoietic stem cell transplantation, have
131 press graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT
132 st disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HCT)
133 eration of immunity is a major problem after allogeneic hematopoietic stem cell transplantation (HCT)
134 etrimental late pulmonary complication after allogeneic hematopoietic stem cell transplantation (HCT)
135                                              Allogeneic hematopoietic stem cell transplantation (HCT)
136                                              Allogeneic hematopoietic stem cell transplantation (HCT)
137 tion in CMV-positive recipients (R(+)) after allogeneic hematopoietic stem cell transplantation (HCT)
138      Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation (HCT)
139  Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT)
140 potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT)
141 r cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HCT)
142 tive care, both long-term survival following allogeneic hematopoietic stem cell transplantations (HSC
143 e a frequent and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT
144 ronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT
145                                              Allogeneic hematopoietic stem cell transplantation (HSCT
146                                              Allogeneic hematopoietic stem cell transplantation (HSCT
147 MVR) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT
148 the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT
149       To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT
150 ess in 48 patients who were >1 year out from allogeneic hematopoietic stem cell transplantation (HSCT
151 th either RAG or ARTEMIS mutations following allogeneic hematopoietic stem cell transplantation (HSCT
152                                Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT
153                                              Allogeneic hematopoietic stem cell transplantation (HSCT
154                                              Allogeneic hematopoietic stem cell transplantation (HSCT
155 ith myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (HSCT
156                                              Allogeneic hematopoietic stem cell transplantation (HSCT
157                                        After allogeneic hematopoietic stem cell transplantation (HSCT
158                                              Allogeneic hematopoietic stem cell transplantation (HSCT
159 CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT
160 xamines reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT
161 or (GVT) effects remains a paramount goal in allogeneic hematopoietic stem cell transplantation (HSCT
162                                     Although allogeneic hematopoietic stem cell transplantation (HSCT
163                                              Allogeneic hematopoietic stem cell transplantation (HSCT
164                      The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT
165 llogeneic T cell response in hosts receiving allogeneic hematopoietic stem cell transplantation (HSCT
166 elapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT
167 lities in acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT
168 e antigen (anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT
169 ion is a potentially serious complication of allogeneic hematopoietic stem cell transplantation (HSCT
170  management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT
171             Their role in human conventional allogeneic hematopoietic stem cell transplantation (HSCT
172 ediction of nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT
173 (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT
174 ycetes have a poor outcome, in particular in allogeneic hematopoietic stem cell transplantation (HSCT
175 d graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT
176 t important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT
177                                              Allogeneic hematopoietic stem cell transplantation (HSCT
178 ith measurable changes in Treg subsets after allogeneic hematopoietic stem cell transplantation (HSCT
179                                              Allogeneic hematopoietic stem cell transplantation (HSCT
180 ral infections are major complications after allogeneic hematopoietic stem cell transplantation (HSCT
181 idity and mortality in patients treated with allogeneic hematopoietic stem cell transplantation (HSCT
182 tologic malignancies not in remission before allogeneic hematopoietic stem cell transplantation (HSCT
183 id Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT
184 mes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT
185 roximately 15,000 to 20,000 patients undergo allogeneic hematopoietic stem cell transplantation (HSCT
186  remains the major barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT
187 ly limits the application and the success of allogeneic hematopoietic stem cell transplantation (HSCT
188 mmune-mediated graft-versus-leukemia effect, allogeneic hematopoietic stem cell transplantation (HSCT
189  microangiopathy (PTMA) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT
190     Human leukocyte antigen (HLA)-mismatched allogeneic hematopoietic stem cell transplantation (HSCT
191 s a similar effect on CMV reactivation after allogeneic hematopoietic stem cell transplantation (HSCT
192 nts with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT
193                     Immunoincompetence after allogeneic hematopoietic stem cell transplantation (HSCT
194                                              Allogeneic hematopoietic stem cell transplantation (HSCT
195 disease (GVHD) and hematopoietic recovery in allogeneic hematopoietic stem cell transplantation (HSCT
196                                              Allogeneic hematopoietic stem cell transplantation (HSCT
197 of morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT
198 st disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT
199 As) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT
200  and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT
201              This report describes the first allogeneic hematopoietic stem cell transplantation (HSCT
202 pstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT
203  solid-organ transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT
204 relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT
205                                              Allogeneic hematopoietic stem cell transplantation (HSCT
206 nt and maintenance of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT
207 viruses may cause severe complications after allogeneic hematopoietic stem cell transplantation (HSCT
208      Despite recent advances in the field of allogeneic hematopoietic stem cell transplantation (HSCT
209 ictive role in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT
210 kinesis 8 (DOCK8) deficiency can be cured by allogeneic hematopoietic stem cell transplantation (HSCT
211                               The outcome of allogeneic hematopoietic stem cell transplantation (HSCT
212 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT
213                                              Allogeneic hematopoietic stem cell transplantation (HSCT
214 (cGVHD) remains a major late complication of allogeneic hematopoietic stem cell transplantation (HSCT
215                                              Allogeneic hematopoietic stem cell transplantation (HSCT
216                                              Allogeneic hematopoietic stem cell transplantation (HSCT
217 sus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT
218                                              Allogeneic hematopoietic stem cell transplantation (HSCT
219 mains a significant cause of morbidity after allogeneic hematopoietic stem cell transplantation (HSCT
220                   The treatment of CIDs with allogeneic hematopoietic stem cell transplantation (HSCT
221                                              Allogeneic hematopoietic stem cell transplantation (HSCT
222                                           In allogeneic hematopoietic stem cell transplantation (HSCT
223 mbotic microangiopathy (TMA) occurring after allogeneic hematopoietic stem cell transplantation (HSCT
224 against tumor recurrence and infection after allogeneic hematopoietic stem cell transplantation (HSCT
225 ns of molecular aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT
226 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT
227 orbidity and mortality in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT
228 ed to be evaluated regarding eligibility for allogeneic hematopoietic stem cell transplantation (HSCT
229  and mediate graft-versus-leukemia following allogeneic hematopoietic stem cell transplantation (HSCT
230 ese types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT
231 mal residual disease (MRD) response, rate of allogeneic hematopoietic stem-cell transplantation (HSCT
232 al residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT
233 the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT
234 ease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT
235 r this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT
236                  Of the cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT
237 nd efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT
238 is of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT
239 us-host disease (GVHD) limits the success of allogeneic hematopoietic stem-cell transplantation (HSCT
240                                              Allogeneic hematopoietic stem-cell transplantation (HSCT
241 gher risk of mortality among Hispanics after allogeneic hematopoietic stem-cell transplantation (HSCT
242 trospective study to evaluate the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT
243 ensity chemotherapy conditioning regimen and allogeneic hematopoietic stem-cell transplantation (HSCT
244 netic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT
245 nor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT
246 ment of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT
247                                              Allogeneic hematopoietic stem-cell transplantation (HSCT
248  Previous observational studies suggest that allogeneic hematopoietic stem-cell transplantation (HSCT
249  report on durable clinical remissions after allogeneic hematopoietic stem cell transplantation in 2
250  highlights the need for early diagnosis and allogeneic hematopoietic stem cell transplantation in af
251              In the 78 patients who received allogeneic hematopoietic stem cell transplantation in CR
252 ive study for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in ol
253             The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in th
254 ally searched for in women who have received allogeneic hematopoietic stem-cell transplantation in an
255 h genital chronic GVHD (cGVHD) who underwent allogeneic hematopoietic stem-cell transplantation in ou
256          Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, incl
257 yeloid leukemia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induc
258            Selection of a suitable graft for allogeneic hematopoietic stem cell transplantation invol
259                                              Allogeneic hematopoietic stem cell transplantation is a
260                                              Allogeneic hematopoietic stem cell transplantation is an
261                                              Allogeneic hematopoietic stem cell transplantation is ha
262                               The utility of allogeneic hematopoietic stem cell transplantation is li
263                              The efficacy of allogeneic hematopoietic stem cell transplantation is li
264                                Myeloablative allogeneic hematopoietic stem-cell transplantation is cu
265         Reduced-intensity conditioning (RIC) allogeneic hematopoietic stem-cell transplantation is po
266 ciency related to R in patients who received allogeneic hematopoietic stem-cell transplantation is un
267 (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, litt
268 ted with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more
269  the genome has significant implications for allogeneic hematopoietic stem cell transplantation, not
270 had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or hi
271        ADA coupled to polyethylene glycol or allogeneic hematopoietic stem cell transplantation rapid
272 stress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recip
273                                          All allogeneic hematopoietic stem cell transplantation recip
274                   On the contrary, long-term allogeneic hematopoietic stem cell transplantation recip
275 udies that focused on MSC treatment of adult allogeneic hematopoietic stem cell transplantation recip
276 d minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, rela
277                                              Allogeneic hematopoietic stem-cell transplantation remai
278 onsidered for reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation (RIC-
279                                              Allogeneic hematopoietic stem cell transplantation (SCT)
280 eplacing myeolablative conditioning prior to allogeneic hematopoietic stem cell transplantation (SCT)
281 hesis that early reconstitution of DCs after allogeneic hematopoietic stem cell transplantation (SCT)
282                                              Allogeneic hematopoietic stem cell transplantation (SCT)
283                                   Therefore, allogeneic hematopoietic stem cell transplantation shoul
284 ell-mediated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, sugg
285 l membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survi
286 f nonmyeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation that
287              A protocol for nonmyeloablative allogeneic hematopoietic stem-cell transplantation that
288 s an important factor for donor selection in allogeneic hematopoietic stem cell transplantation, the
289  Two patients died early in childhood; after allogeneic hematopoietic stem-cell transplantation, the
290 es to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to pr
291                                              Allogeneic hematopoietic stem cell transplantation was o
292                                              Allogeneic hematopoietic stem cell transplantation was t
293 upper GI tract on 201 patients who underwent allogeneic hematopoietic stem cell transplantation were
294  that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were
295 s despite improved treatment options such as allogeneic hematopoietic stem cell transplantation, whic
296 disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation which
297 Wider application of immunotherapies such as allogeneic hematopoietic stem cell transplantation with
298 vasan et al report that mice conditioned for allogeneic hematopoietic stem cell transplantation with
299               This study reports outcomes of allogeneic hematopoietic stem cell transplantation with
300 d immune deficiency (SCID) may be treated by allogeneic hematopoietic stem cell transplantation witho

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top